Neomycin Polymyxin: How the Antibiotic Combination Works

Neomycin and polymyxin B are two antibiotics that work through completely different mechanisms and target different groups of bacteria, which is exactly why they are combined in so many over-the-counter and prescription products. You will find the pair in wound-care ointments, ear drops, and eye drops, sometimes alongside a third antibiotic like bacitracin or gramicidin, and sometimes with a steroid like hydrocortisone or dexamethasone. The combination has been a pharmacy staple for decades, but the evidence on when it actually helps, when plain petroleum jelly works just as well, and when the duo can cause problems is more nuanced than the products’ ubiquity suggests.

How the Two Antibiotics Work

Neomycin belongs to the aminoglycoside family. It kills bacteria by binding to a specific site on the bacterial ribosome, the machinery cells use to build proteins. Once neomycin locks onto that site, the ribosome misreads the genetic instructions it is translating, producing faulty proteins or stalling production altogether. The bacterium cannot survive the resulting chaos.¹ Neomycin is effective against many common gram-positive bacteria, like Staphylococcus aureus, and some gram-negative species.

Polymyxin B takes an entirely different approach. Instead of disrupting the protein-building process, it targets the outer membrane of gram-negative bacteria. Polymyxin B molecules bind to lipopolysaccharides, the large molecules that make up the outer wall of gram-negative organisms, and destabilize the membrane’s structure.² Molecular simulations have shown that this binding loosens the packing of the outer membrane, triggers phospholipids to flip between layers, and eventually creates defects that allow more polymyxin molecules to punch through. The inner membrane is then disrupted in a similar way, and the bacterium essentially leaks to death.³

Because neomycin sabotages protein production while polymyxin B tears apart cell membranes, the two antibiotics attack bacteria on two fronts at once. A bacterium that can shrug off one mechanism still has to contend with the other.

Why Combining Them Matters More Than Either Alone

The clinical rationale behind the pairing is not just a broader kill list. The two antibiotics are genuinely synergistic against certain organisms, meaning the combination is more potent than you would expect from simply adding their individual effects. Lab testing has demonstrated that a neomycin-polymyxin B combination reduced the concentrations needed to inhibit or kill bacteria by three to four times compared with either drug alone for pathogens commonly found in ear infections. Against Pseudomonas aeruginosa specifically, the synergistic boost was even larger, with the effective concentration dropping five- to six-fold.⁴ That same study found the combination outperformed ciprofloxacin, a commonly prescribed single-agent antibiotic, in head-to-head lab tests against outer-ear infection pathogens.

When bacitracin joins the mix to form triple-antibiotic ointment, the spectrum widens further. Lab analysis using fractional inhibitory concentration indices showed synergy between neomycin and bacitracin against both S. aureus and Ps. aeruginosa, and between neomycin and polymyxin B against Enterococcus faecalis.⁵ The three-drug combination showed synergistic or additive effects against every organism tested in that study, giving a good explanation for why triple-antibiotic ointment has remained a go-to wound-care product for so long.

Common Formulations and Where They Are Used

The neomycin-polymyxin pairing shows up in several product categories, each tailored to a different part of the body. Understanding what else is in the tube or bottle matters, because the added ingredients shift the product’s purpose.

Wound ointments: Triple-antibiotic ointment combines neomycin, polymyxin B, and bacitracin in a petrolatum base. It is sold over the counter for minor cuts, scrapes, and burns.⁶ “Double antibiotic” ointment drops neomycin and keeps only polymyxin B and bacitracin, partly to reduce the allergy risk discussed below.
Ear drops: Prescription otic solutions pair neomycin and polymyxin B with hydrocortisone to treat outer-ear infections. The steroid component addresses swelling and pain. A clinical trial comparing an antibiotic ointment with and without hydrocortisone for acute otitis externa found that adding the steroid improved individual symptom relief.⁷
Eye drops: Ophthalmic formulations typically combine neomycin and polymyxin B with gramicidin (another antibiotic) for bacterial conjunctivitis. Trials comparing this combination with trimethoprim-polymyxin B eye drops found no significant difference in how well either cleared infections or eradicated organisms.⁸
Burn wound care: More complex compounded preparations that include neomycin and polymyxin B alongside silver sulfadiazine, nystatin, and bacitracin have been tested in burn units, where the stakes of wound infection are highest. One study found these compounded mixtures effective against every single bacterial isolate tested from burn wounds.⁹

Do You Actually Need Antibiotic Ointment for Minor Wounds?

This is where the conventional wisdom runs into some uncomfortable evidence. Most people reach for triple-antibiotic ointment after a scrape because they assume it prevents infection better than keeping the wound moist with plain petrolatum. The data suggests the antibiotic component may not be pulling its weight for routine minor wounds.

A controlled study comparing a petrolatum-based wound protectant (containing no antibiotics) against a polymyxin B/bacitracin ointment found no difference in erythema, edema, tissue regrowth, crusting, or scabbing at any measured time point. The antibiotic ointment did cause more burning at the one-week mark, and one case of allergic contact dermatitis was reported in the antibiotic group.¹⁰ A companion study using a laser wound model went further: the petrolatum-based protectant actually outperformed both double-antibiotic and triple-antibiotic ointments on measures of redness, swelling, and tissue healing, with significant differences persisting from day 7 through day 18. Subjects themselves ranked the non-antibiotic ointment as best and the triple-antibiotic ointment as worst.¹¹

The takeaway is not that neomycin-polymyxin products are useless, but that for clean, minor wounds after dermatologic procedures, keeping the wound moist with an inert barrier may be enough. The antibiotics make more clinical sense for wounds that are contaminated, larger, or in people who are immunocompromised. For everyday kitchen nicks, you may be getting the allergy risk without a meaningful healing benefit.

Contact Allergy to Neomycin

Neomycin is one of the most common causes of allergic contact dermatitis from topical medications, and this is the single biggest practical concern with any product that contains it. A systematic review and meta-analysis found the pooled prevalence of contact allergy to neomycin to be about 3% in adults and roughly 4% in children. The rates are not evenly distributed: North America has the highest prevalence, around 6% in adults and 8% in children, while Europe shows much lower rates, around 2.5% in adults.¹² The higher North American numbers likely reflect the heavy over-the-counter availability and cultural habit of applying antibiotic ointment to every minor wound.

The allergy is a delayed-type reaction, meaning it does not show up immediately. You might use neomycin-containing ointment for several days before the treated area becomes red, itchy, and inflamed, making it easy to confuse with a worsening infection. That confusion can lead people to apply more ointment, making the reaction worse. A Danish cross-sectional study spanning 2000 to 2023 found an overall allergy prevalence of about 1.4%, with the rate declining in recent years, from roughly 1.8% before 2010 to 1.2% afterward. The allergy was more common in people over 40 and in those with facial dermatitis.¹³

If you develop contact allergy to neomycin, you should also be cautious with other aminoglycoside antibiotics. Cross-reactivity within this drug class is well documented because the drugs share structural features.¹⁴ Patch testing in neomycin-allergic patients found that 55% also reacted to gentamicin, a widely used injectable aminoglycoside.¹⁵ This is worth mentioning to a doctor if you ever need systemic aminoglycoside treatment for a serious infection. Polymyxin B itself, meanwhile, is rarely the allergen in these combination products.

Ear Drops and the Ototoxicity Question

When neomycin-polymyxin ear drops are prescribed for infections of the outer ear canal, a common worry is whether the neomycin could damage hearing. Aminoglycosides as a class are known to be ototoxic when they reach the inner ear at sufficient concentrations. In most outer-ear infections, the eardrum is intact and acts as a barrier, keeping the drops in the canal and away from the delicate structures of the inner ear. The concern escalates when the eardrum has a perforation or when a tube is in place.

A study examining sensorineural hearing loss in patients with non-intact eardrums who used neomycin-containing drops found that short-term use, meaning a single prescription course, was not associated with an increased risk of hearing loss. However, repeated courses, defined as two or more prescriptions, did show a significant association with hearing damage.¹⁶ This is why many ear, nose, and throat specialists prefer fluoroquinolone ear drops (like ofloxacin or ciprofloxacin) for patients with perforated eardrums or tympanostomy tubes. If your eardrum is intact and you are treating a straightforward swimmer’s ear infection, a single course of neomycin-polymyxin-hydrocortisone drops is generally considered safe. The risk profile changes with repeated use or a compromised eardrum.

Concerns About Antibiotic Resistance

Any conversation about antibiotics eventually arrives at resistance, and neomycin-polymyxin products are not exempt from the discussion. The picture, though, is more complex than a simple “topical antibiotics cause superbugs” narrative.

On one hand, the redundancy built into multi-antibiotic formulations appears to offer some protection against resistance emergence. A study that tracked bacterial susceptibility over time found that, with the exception of certain Proteus species, 90% or more of bacteria tested remained susceptible to at least one of the antimicrobial agents in a multi-drug topical mixture. The authors concluded that the overlapping coverage reduced the likelihood that resistant organisms would persist during clinical use.¹⁷

On the other hand, research on individual over-the-counter antibiotics paints a less reassuring picture. Exposing bacteria to use-level concentrations of neomycin in the lab produced a dramatic increase in resistance in Streptococcus pyogenes, with the minimum inhibitory concentration climbing 5,000-fold above baseline. Bacitracin exposure caused stable resistance in S. aureus and Acinetobacter baumannii, and cross-resistance to other clinically important antibiotics, including ciprofloxacin and gentamicin, was demonstrated after exposure to bacitracin or tyrothricin.¹⁸ These are lab findings and do not directly prove that rubbing triple-antibiotic ointment on a scrape will generate resistant bacteria in the wild, but they do suggest that the casual, widespread use of these products is not without consequences for resistance.

A separate concern involves drug-drug interference within combination products. Research has shown that gramicidin and tyrothricin, membrane-active agents sometimes included in over-the-counter antibiotic preparations, can actually reduce the bactericidal activity of aminoglycosides like neomycin. The mechanism appears to involve disruption of the membrane electrical potential that aminoglycosides need to enter bacteria.¹⁹ This is a subtle but important finding: in some formulations, one ingredient may be partially shielding bacteria from another. Whether this effect is clinically significant in topical wound or eye-drop use remains an open question, but it challenges the assumption that more antibiotics in a product always means better killing.

Who Should Avoid These Products

Given all of the above, there are clear situations where neomycin-polymyxin products are a poor fit. Anyone with a known or suspected neomycin allergy should switch to a neomycin-free alternative. If you have had a reaction to gentamicin or another aminoglycoside, the cross-reactivity risk means neomycin products should also be avoided. For people with perforated eardrums or ear tubes who need repeated courses of ear drops, a fluoroquinolone drop is a safer bet for preserving hearing. And for routine wound care on clean, minor injuries in otherwise healthy individuals, the evidence suggests that plain petrolatum or a non-antibiotic wound protectant provides equivalent healing without the allergy risk or the low-level resistance concern.

The combination still earns its place in scenarios where infection risk is genuinely elevated: contaminated wounds, burn care, active ear or eye infections where a doctor has judged that antibiotic coverage is warranted. The key is matching the product to the problem rather than defaulting to antibiotics out of habit. A tube of triple-antibiotic ointment in the medicine cabinet is not harmful to own, but reaching for it every time you get a paper cut is probably doing more for your peace of mind than for the wound.

How Polymyxins Went From Forgotten to Revived

Polymyxin antibiotics have an unusual backstory that explains why they ended up mostly in topical products rather than pills or IV bags. First discovered in the 1940s, polymyxins initially fell out of favor for systemic use because they could damage the kidneys. For decades, their main clinical home was in ointments, ear drops, and eye drops, where the drug stays local and systemic absorption is minimal. But the global rise of multidrug-resistant gram-negative bacteria, combined with a thin pipeline of new antibiotics, brought intravenous polymyxins (particularly colistin, also called polymyxin E) back into use as a last-resort treatment for infections that resist everything else.²⁰ This revival has driven renewed research into how polymyxins interact with bacterial membranes and how resistance to them develops. It also adds another dimension to the resistance conversation: polymyxins are now a critical safety net in hospitals, which makes any factor that could erode their effectiveness, including widespread casual use in topical products, worth watching more carefully than it was a generation ago.